Early diagnosis of Alzheimer’s disease is important to ensure timely and accurate treatment. We show that a blood-based circular RNA signature can accurately detect Alzheimer’s disease as well as, or better than, current biomarkers and even predict who will develop symptoms before they appear. This less invasive approach could offer earlier diagnosis and improved monitoring of Alzheimer’s disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
Subscribe to this journal
Receive 12 print issues and online access
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Subjects
References
Self, W. K. & Holtzman, D. M. Emerging diagnostics and therapeutics for Alzheimer disease. Nat. Med. 29, 2187–2199 (2023). A review that presents a summary of new, increasingly sensitive blood-based biomarkers and the first generation of disease‑modifying therapies.
Petersen, K. K. et al. Predicting onset of symptomatic Alzheimer’s disease with plasma p-tau217 clocks. Nat. Med. 32, 1085–1094 (2026). This paper shows that plasma pTau217 is a highly accurate blood-based biomarker for AD and changes before clinical symptoms.
Gong, K. et al. High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed-dementia cohort. Mol. Neurodegener. 20, 120 (2025). This paper shows AD leads to major plasma proteomic changes beyond pTau217, and those changes capture other relevant pathways.
Dube, U. et al. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nat. Neurosci. 22, 1903–1912 (2019). This paper reports the first brain circRNA atlas in the context of AD, which identifies a large number of circRNAs associated with AD.
Fernandez, M. V. et al. Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center. Sci. Data 11, 768 (2024). This paper describes the Knight-ADRC cohort and all the available clinical and molecular data, which are instrumental for the discovery of the circRNA signature.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Phillips, B. et al. Blood-based circular RNAs for early diagnosis of Alzheimer’s disease. Nat. Med. https://doi.org/10.1038/s41591-026-04485-5 (2026).
Rights and permissions
About this article
Cite this article
Early detection of Alzheimer’s disease with circular RNA from blood. Nat Med 32, 2745–2746 (2026). https://doi.org/10.1038/s41591-026-04563-8
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-026-04563-8
